Recent Finacing
Recent Raise
Adaptimmune is an Oxford-based biotechnology company developing engineered T-cell therapies that reprogram patients' T cells to target cancers, conducting clinical trials in multiple myeloma, melanoma, sarcoma, and ovarian cancer.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors